Project Grant R03AI141031

This $304,742 Project Grant awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel low-cost intradermal delivery platform for nucleic acid vaccines. The project aims to create a handheld pen device that can deliver electrical pulses through microelectrodes to create temporary pores in skin cells, allowing direct vaccine delivery to immune cells without the need for lipid nanoparticles (LNPs) or...

This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $303,173 to Gateway Bio Inc. to develop a novel stealth lipid formulation for use in an HIV vaccine targeting the membrane-proximal external region (MPER) of the HIV envelope. The goal is to address a key challenge that led to the previous HVTN 133 clinical trial being halted - a polyethylene...

This federal Project Grant award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a therapeutic nucleic acid vaccine for chronic hepatitis B virus (HBV) infections in HIV/HBV co-infected individuals. The awardee, Orlance, Inc., a woman-owned small business in Seattle, Washington, is leveraging its innovative MACH-1 gene gun technology to efficiently deliver DNA...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $919,501 to Emmune Inc. to develop a non-viral gene therapy platform using ECD4-IG, an antibody-like therapeutic protein, to suppress HIV replication for a lifetime after a single intramuscular injection. The goal is to achieve a functional cure for HIV by sustaining therapeutically-effective plasma...

This $251,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support a clinical trial planning project focused on evaluating the use of adeno-associated virus (AAV)-delivered broadly neutralizing antibodies (bnAbs) to achieve durable control of HIV-1 in children after discontinuation of antiretroviral therapy (ART). The award to the University of Massachusetts Medical School will help develop a full...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...

This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,105,240 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of California, Davis. This funding will support a collaborative HIV vaccine research program, referred to as OPTI-FLIP, that aims to develop a vaccine regimen leveraging cooperative interactions between antibody and T-cell immune responses. The key research activities funded under this grant...

This federal Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $887,626 to the University of Miami to conduct research focused on preventing immune responses towards adeno-associated virus (AAV)-delivered anti-HIV antibodies. The project aims to explore two strategies to induce tolerance and prevent anti-drug antibody (ADA) formation in response to AAV-mediated gene therapy delivering broadly neutralizing HIV...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), has awarded a Project Grant of $423,500 to Loyola University of Chicago's Health Sciences Campus to develop a novel mucosal cytotoxic T-lymphocyte (CTL)-based HIV vaccine. The project aims to create an HIV vaccine that can exclusively induce HIV-specific CD8+ CTLs, without eliciting HIV-specific CD4+ T cells, in order to confer protection...